

ARTICLE OPEN



Broadening the phenotypic and molecular spectrum of FINCA syndrome: Biallelic *NHLRC2* variants in 15 novel individuals

Henrike L. Sczakiel^{1,2,3}, Max Zhao^{1,2,4}, Brigitte Wollert-Wulf^{5,6,7}, Magdalena Danyel^{1,8}, Nadja Ehmke^{1,4}, Corinna Stoltenburg⁹, Nadirah Damseh¹⁰, Motee Al-Ashhab¹⁰, Tugce B. Balci¹¹, Matthew Osmond¹², Andrea Andrade¹³, Jens Schallner¹⁴, Joseph Porrman¹⁵, Kimberly McDonald¹⁶, Mingjuan Liao¹⁷, Henry Oppermann¹⁸, Konrad Platzer¹⁸, Nadine Dierksen¹⁹, Majid Mojarrad²⁰, Atieh Eslahi²⁰, Behnaz Bakaeen²¹, Daniel G. Calame^{22,23,24}, James R. Lupski^{23,24,25,26}, Zahra Firoozfar²⁷, Seyed Mohammad Seyedhassani²⁸, Seyed Ahmad Mohammadi^{29,30}, Najwa Anwaar³¹, Fatima Rahman³¹, Dominik Seelow^{1,32}, Martin Janz^{5,6,7}, Denise Horn¹, Reza Maroofian³³ and Felix Boschann^{1,4,8}✉

© The Author(s) 2023

FINCA syndrome [MIM: 618278] is an autosomal recessive multisystem disorder characterized by fibrosis, neurodegeneration and cerebral angiomatosis. To date, 13 patients from nine families with biallelic *NHLRC2* variants have been published. In all of them, the recurrent missense variant p.(Asp148Tyr) was detected on at least one allele. Common manifestations included lung or muscle fibrosis, respiratory distress, developmental delay, neuromuscular symptoms and seizures often followed by early death due to rapid disease progression.

Here, we present 15 individuals from 12 families with an overlapping phenotype associated with nine novel *NHLRC2* variants identified by exome analysis. All patients described here presented with moderate to severe global developmental delay and variable disease progression. Seizures, truncal hypotonia and movement disorders were frequently observed. Notably, we also present the first eight cases in which the recurrent p.(Asp148Tyr) variant was not detected in either homozygous or compound heterozygous state.

We cloned and expressed all novel and most previously published non-truncating variants in HEK293-cells. From the results of these functional studies, we propose a potential genotype-phenotype correlation, with a greater reduction in protein expression being associated with a more severe phenotype.

Taken together, our findings broaden the known phenotypic and molecular spectrum and emphasize that *NHLRC2*-related disease should be considered in patients presenting with intellectual disability, movement disorders, neuroregression and epilepsy with or without pulmonary involvement.

European Journal of Human Genetics; <https://doi.org/10.1038/s41431-023-01382-0>

¹Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institut für Medizinische Genetik und Humangenetik, Augustenburger Platz 1, 13353 Berlin, Germany. ²Max Planck Institute for Molecular Genetics, RG Development & Disease, Ihnestr. 63-73, 14195 Berlin, Germany. ³Berlin Institute of Health at Charité – Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité Junior Clinician Scientist Program, Charitéplatz 1, 10117 Berlin, Germany. ⁴Berlin Institute of Health at Charité – Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany. ⁵Biology of Malignant Lymphomas, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin 13125, Germany. ⁶Experimental and Clinical Research Center, a cooperation between the Max Delbrück Center for Molecular Medicine in the Helmholtz Association and the Charité - Universitätsmedizin Berlin, Berlin 13125, Germany. ⁷Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, Berlin 13125, Germany. ⁸Berlin Institute of Health at Charité – Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité Clinician Scientist Program, Charitéplatz 1, 10117 Berlin, Germany. ⁹Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Sozialpädiatrisches Zentrum Neuropädiatrie, Augustenburger Platz 1, 13353 Berlin, Germany. ¹⁰Department of Pediatrics and Genetics, Al Makassed Hospital and Al-Quds University, Jerusalem, Palestine. ¹¹Medical Genetics Program of Southwestern Ontario, London Health Sciences Centre, Western University, London, ON, Canada. ¹²Children's Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa, ON, Canada. ¹³Division of Pediatric Neurology, London Health Sciences Centre, Western University, London, ON, Canada. ¹⁴Department of Sozialpädiatrisches Zentrum, Klinik fuer Kinder und Jugendmedizin, Universitaetsklinikum Dresden, Fetscherstrasse 74, 01307 Dresden, Germany. ¹⁵Institute for Clinical Genetics, Universitätsklinikum, Technischen Universität Dresden, Dresden, Germany. ¹⁶Pediatric Neurology, University of Mississippi Medical Center, Jackson, MS, USA. ¹⁷GeneDx, LLC, Gaithersburg, MD 20877, USA. ¹⁸Institute of Human Genetics, University of Leipzig Medical Center, 04103 Leipzig, Germany. ¹⁹Evangelisches Krankenhaus Oberhausen, Oberhausen, Germany. ²⁰Department of Medical Genetics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. ²¹Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran. ²²Section of Pediatric Neurology and Developmental Neurosciences, Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA. ²³Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA. ²⁴Texas Children's Hospital, Houston, TX 77030, USA. ²⁵Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX 77030, USA. ²⁶Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA. ²⁷Palindrome, Isfahan, Iran. ²⁸Dr. Seyedhassani Medical Genetic Center, Yazd, Iran. ²⁹Meybod Genetics Research Center, Yazd, Iran. ³⁰Yazd Welfare Organisation, Yazd, Iran. ³¹Department of Developmental - Behavioral Pediatrics, University of Child Health Sciences and The Children's Hospital, Lahore, Pakistan. ³²Bioinformatics and Translational Genetics, Berlin Institute of Health at Charité-Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany. ³³Department of Neuromuscular Diseases, University College London, Queen Square, Institute of Neurology, London WC1N 3BG, UK. ✉email: felix.boschann@charite.de

Received: 9 November 2022 Revised: 17 April 2023 Accepted: 26 April 2023

Published online: 15 May 2023

INTRODUCTION

The *NHL repeat containing 2 (NHLRC2)* gene (HGNC: 24731) encodes a ubiquitously expressed and well conserved protein consisting of an N-terminal thioredoxin domain (TRX) and a large NHL repeat domain. The exact function remains elusive and only few functional studies have been conducted [1]. Nishi and colleagues showed that *NHLRC2* plays a role in reactive oxygen species (ROS)-induced apoptosis and that the loss of *NHLRC2* results in increased sensitivity to ROS-induced cell death [2]. Using genome-wide CRISPR screening, Haney and colleagues identified *NHLRC2* as a regulator of phagocytosis involved in actin polymerization and filopodia formation [3]. Recently, an *NHLRC2* knockout mouse model revealed embryonic lethality due to gastrulation failure [4].

In 2018, Uusimaa and colleagues identified the same compound heterozygous variants in *NHLRC2* in three individuals from two non-consanguineous families of Finnish descent as the cause of a cerebral-pulmonary disorder [MIM: 618278] [5]. They named this novel syndrome FINCA disease based on manifestations observed at tissue level: fibrosis, neurodegeneration and cerebral angiomas. All patients developed feeding difficulties and growth retardation within the first two months of life. The disease progressed rapidly and all died before the age of two, probably due to severe respiratory distress. Brain magnetic resonance imaging (MRI) scans and post-mortem histopathology revealed brain atrophy, vacuolar white matter degeneration and interstitial lung fibrosis. While further studies in patients carrying biallelic *NHLRC2* variants confirmed this severe multisystem phenotype [6], cases with predominantly neurological involvement and survival into the second decade of life have also been reported [7, 8]. In all 13 individuals described so far, the recurrent missense variant c.442G>T, p.(Asp148Tyr) was present either in homozygous or compound heterozygous state. Respiratory defects and altered lung morphology were observed in nine individuals, highlighting pulmonary findings as a common feature of *NHLRC2*-related disease.

Here, we present nine novel *NHLRC2* variants detected in 15 additional individuals with various neurological symptoms, thereby expanding the allelic series and broadening the phenotypic spectrum of *NHLRC2*-related disease.

MATERIALS AND METHODS

This study adheres to the principles set out in the Declaration of Helsinki and was approved by institutional Ethics Committees of Charité - Universitätsmedizin (EA2/177/18). We recruited the affected individuals 1 and 2 via the TRANSLATE-NAMSE project, an Undiagnosed Disease Program at Charité - Universitätsmedizin Berlin [9]. Probands 3-15 were identified through matches within GeneMatcher and across the Matchmaker Exchange, and by checking the ClinVar database for recently submitted variants [10-12]. All *NHLRC2* variants were detected by exome sequencing (ES) and classified according to the ACMG guidelines [13] and refer to MANE transcript (NM_198514.4). Informed consent was obtained for each participant.

Lymphoblastoid cell lines (LCLs)

B cells were isolated from patients' heparin whole blood samples and immortalized by Epstein-Barr virus (EBV) transfection as previously described [14]. Established LCLs were cultured at 37 °C and 5% CO₂ in RPMI-1640 with L-Glutamine supplemented with 10% fetal calf serum (FCS) and Penicillin/Streptomycin (all purchased from: Gibco™, Thermo Fisher Scientific, Waltham, Massachusetts, USA).

RT-qPCR and cDNA sequencing of LCLs, Western blots

A detailed description of RT-qPCR and cDNA sequencing of LCLs and Western blots can be found in Supplementary File 1.

Generation of expression constructs for *NHLRC2* non truncating variants

Sequences of wildtype and mutant *NHLRC2* with an added C-terminal Flag-tag and XhoI and XbaI restriction sites were amplified from cDNA of LCLs.

Amplified fragments were either cloned directly into pcDNA.3 via XhoI and XbaI or into pJETeasy and subsequently subcloned from pJETeasy into pcDNA.3. Final pcDNA.3 constructs were checked for correct integration of the respective *NHLRC2* variant by Sanger sequencing.

For generation of non-truncating variants where no prior LCL had been available, the respective mutation was introduced via primers and a 5' and 3' partial fragment carrying the respective mutation in a 30 bp common overlap were amplified from wildtype *NHLRC2* cDNA. Fragments were assembled via overlap extension PCR and either directly cloned into pcDNA.3 or first assembled into pBluescript(-) via overlap extension PCR and subsequently subcloned into pcDNA.3. A complete list of the generated variants, fragments and used primers can be found in Supplementary Table 1.

Transfection of HEK293 cells

HEK293 were seeded at 5×10^5 cells per well in a 6-well-plate in DMEM medium supplemented with 10% FCS, Penicillin/Streptomycin, sodium pyruvate, and GlutaMAX™ the day before transfection (FCS: #F7524-500 ml LOT:#BCBW1925, Sigma-Aldrich, St. Louis, Missouri, USA; DMEM and all other supplements: Gibco™, Thermo Fisher Scientific, Waltham, Massachusetts, USA). 1 µg *NHLRC2*-pcDNA.3 plasmid and 0.5 µg GFP plasmid were transfected into HEK293 cells using CaPO₄-transfection (50 µl of 2.5 M CaCl₂ added to 450 µl DNA in H₂O, then mixed well before dropwise adding into 500 µl of 2xHBS [50 mM HEPES, 280 mM NaCl, 1.5 mM Na₂HPO₄] under continuous vortexing and subsequent dropwise addition onto HEK293 cells). Medium was changed to fresh medium after 6 h and cells were grown for 48 h in total after transfection before harvest of cell pellets. Whole cell protein lysate was extracted from flash frozen cell pellets using high salt lysis buffer (20 mM HEPES pH 7.9, 350 mM NaCl, 1 mM MgCl₂, 0.5 mM EDTA, 0.1 mM EGTA, 0.02% NP40, 1 mM DTT, 2 mM Na-orthovanadate, 1 mM NaF, 1 tablet per 5 ml of cOmplete™ Mini EDTA-free Protease Inhibitor Cocktail).

In silico protein modelling

Computational predictions of the protein structure were generated for wildtype *NHLRC2* and all variants with an expected altered amino-acid sequence. Predictions were computed using a simplified AlphaFold model (v2.2.4) using Colabatory by Google. The computations were performed with default configuration parameters and a randomized seed value. Structural dissimilarity between mutant and wildtype structure was measured by the predicted local-distance difference test (pLDDT), a score of local structural configuration differences predicted from the model loss [15]. Protein-protein interaction (PPI) site predictions were computed for each protein structure using MaSIF (commit: 2a37051) and visualized with pymol [16].

Homozygosity mapping

Homozygosity mapping was performed for families A and F using the AutozygosityMapper [17] as described previously [18].

RESULTS

Clinical spectrum

The clinical findings of the 15 individuals are summarized in Table 1. Comparison of the clinical presentation of this cohort with previously reported cases is summarized in Table 2. Pedigrees are shown in Fig. 1a and detailed clinical reports are provided in Supplementary File 2 and Supplementary Figure 1.

Our cohort of new cases comprised 15 individuals (ten females and five males) from 12 unrelated families. Consanguinity was reported in seven of them. All documented birth measurements were within the normal range. Postnatal adaptation and development in the first weeks of life were unremarkable in 14 of the 15 children. Only one child (individual 5) developed postnatal complications in the form of respiratory distress and pulmonary hypertension. In the following months, recurrent upper respiratory tract infections, anemia and hepatomegaly were noted, and she died prematurely of viral pneumonia at two years of age. All other individuals were aged between 30 months and 19 years at the last follow-up. Thirteen of the 15 individuals had no respiratory or pulmonary symptoms. At the last clinical examination, four

Table 1. Clinical information.

ID	Family A	Family B	Family C	Family D	Family E	Family F	Family G	Family H	Family I	Family J	Family K	Family L			
Gender	Female	Female	Female	Female	Female	Male	Male	Male	Female	Female	Female	Female			
Individual 1	Individual 2	Individual 3	Individual 4	Individual 5	Individual 6	Individual 7	Individual 8	Individual 9	Individual 10	Individual 11	Individual 12	Individual 13	Individual 14	Individual 15	
NHLRC2 variant (NM_198514.4; NP_94091.6.2)	c.1A>G, p.(Met17)	c.442G>T, p.(Asp148Tyr)	c.1750delC, p.(Leu584*)	c.148C>T, p.(Gln50*)	c.109A>C, p.(Gln365Pro)	c.1A>G, p.(Met17)	c.442G>T, p.(Asp148Tyr)	c.442G>T, p.(Asp148Tyr)	c.97_99del, p.(Glu33del)	c.998_1000del, p.(Gln333del)	c.442G>T, p.(Asp148Tyr)	c.442G>T, p.(Asp148Tyr)	c.442G>T, p.(Asp148Tyr)		
Zygoty	Homozygous	Homozygous	Compound-heterozygous	Compound-heterozygous	Compound-heterozygous	Homozygous	Homozygous	Homozygous	Homozygous	Compound-heterozygous	Homozygous	Homozygous	Homozygous	Homozygous	
Allele frequency (gnomAD v2.2.1)	-	0.04%	0.003%	0.0006%	0.0003%	-	0.04%	0.04%	-	0.0004%	0.04%	0.04%	0.04%	0.04%	
ACMG classification	Likely pathogenic	Pathogenic	Likely pathogenic	Pathogenic	VUS	Likely pathogenic	Pathogenic	Pathogenic	VUS	VUS	Pathogenic	Pathogenic	Pathogenic	Pathogenic	
Familial History and Perinatal Period															
Ancestry	Syria	Palestine	Belgian, Hungarian, English, and Scottish	German	African American, Scandinavian, Irish, English, German	Libanon	Iran	Iran	Caucasian	Iran	Pakistan	Iran			
Consanguinity	+	+	-	-	-	+	+	+	-	-	+	+	+	-	
Pregnancy	Unremarkable	Unremarkable	Effexor 75mg q.d. throughout pregnancy, diclectin due to morning sickness, severe migraines	Unremarkable	Pre-eclampsia leading to induction at 37 weeks	Unremarkable	Unremarkable	Unremarkable	Unremarkable	Unremarkable	Unremarkable	Unremarkable	Unremarkable	Unremarkable	
Number of miscarriages	3	None	None	2	None	None	None	None	None	None	None	None	1	1	
Growth Parameters															
Gestational age (weeks)	39 + 1	N/A	40 + 0	40 + 3	37 + 0	40 + 0	40 + 0	36 + 0	40 + 0	full term	39 + 4	N/A	37	37	
Birth length (cm)	53 (+1.1 SD)	N/A	48 (-1.7 SD)	52 (-0.3 SD)	N/A	N/A	N/A	46 (-1.2 SD)	49 (-1.5 SD)	N/A	N/A	49	N/A	53 (+1.1 SD)	
Birth weight (g)	3200 (-0.1 SD)	3300	2800 (-0.9 SD)	3300 (-0.8 SD)	3005 (-0.2 SD)	N/A	N/A	2900 (+0.1 SD)	3300 (-0.7 SD)	N/A	3200 (-0.5 SD)	3000	N/A	3520 (-0.9 SD)	
Head circumference (cm)	33 (-1.0 SD)	N/A	33.5 (-1.1 SD)	34 (-1.3 SD)	N/A	N/A	N/A	32 (-1.1 SD)	34 (-1.2 SD)	N/A	N/A	34	N/A	32 (-1.7 SD)	
Age at last examination	5y 10m	19y	2y 8m	22m	13y 10m	19y	9y 11m	8y	5y	8y	14y	10y	7y	6y 8m	
Height (cm)	100 (-3.0 SD)	150 (-3.7 SD)	90 (-0.6 SD)	87 (+0.6 SD)	160 (0 SD)	163 (-1.5 SD)	115 (-3.7 SD)	124 (-0.7 SD)	99 (-2.1 SD)	118 (+0.2 SD)	149 (-2.2 SD)	132 (-1.1 SD)	18 (-2.1 SD)	108 (-2.2 SD)	
Weight (kg)	13.5 (-3.5 SD)	22 kg (-4 SD) at age 13y	11.6 (-1.3 SD)	9 (-2.0 SD)	49.4 (+0.1 SD)	52.5 (-2.4 SD)	23 (-2.3 SD)	25 (-0.2 SD)	11.5 (-4.6 SD)	18.2 (-0.9 SD)	42 (-1.7 SD)	24 (-2.1 SD)	109 (-2.9 SD)	18 (-1.4 SD)	
Head circumference (cm)	48 (-2.6 SD)	54 (-2.0 SD)	46.7 (-1.1 SD)	46 (-1.7 SD)	N/A	54 (-1.9 SD)	N/A	50 (-2.5 SD)	NA	N/A	55 (0.3 SD)	NA	48.5 (-2.5 SD) at 5y	53 (1.3 SD)	
Psychomotor Development															
Motor development in general	Delayed, broad-based, imbalanced gait	Severe delay; since 6y of age wheelchair-bound	Delayed, broad-based, imbalanced gait	Severe delay	Normal early developmental milestones but poor coordination and core strength	Severely delayed, wheelchair-bound	Severely delayed, wheelchair-bound	Severely delayed, wheelchair-bound	Delayed	Delayed	Delayed	Delayed	Delayed	Delayed	Delayed
Sitting	1y	1y	1y	Not achieved	Achieved in time	8m	Not documented	10m	Not achieved	18m	8m	11m	1y	18m	

Table 1. continued

	Family A	Family B	Family C	Family D	Family E	Family F	Family G	Family H	Family I	Family J	Family K	Family L
Walking unaided	2.5 y	4 y	19 m	Not achieved	1 y	Not achieved	Not achieved	Not achieved	Not achieved	1 y 8 m	1 y 8 m	2.5 y
First words	Nonverbal	Nonverbal	Few words as a toddler	Nonverbal	18 m	Nonverbal	Nonverbal	Nonverbal	Essentially nonverbal	6 y	3.5 y	9 m
Speech	Nonverbal	Nonverbal	Nonverbal	Nonverbal	Few rudimentary words (speech apraxia)	Nonverbal	Nonverbal	Nonverbal	Few rudimentary words	Few rudimentary words	Two word sentences	Nonverbal
Developmental regression	Motor	Motor	Speech and motor regression after 9 m with some developmental progression	N/A	N/A	N/A	-	N/A	N/A	-	-	Speech regression (two words to nonverbal)
Intellectual disability (mild, moderate, severe)	Moderate/severe	Moderate/severe	Severe	Severe	Mild/moderate	Severe	Moderate	Severe	Moderate	Moderate	Moderate/severe	Moderate
Behaviour	-	-	Dysregulated impulsive behaviour, obsessive eating behaviours	-	-	-	-	Autistic behaviour, sleeping disturbances	Hand flapping, rocking	Anxious behaviour, phobia noise, cars, height	-	Autistic, hyperactive behaviour, sleeping disturbances
Brain MRI	At 2.5 y of age: unremarkable	At 2 y of age: mild cortical atrophy, dilated lateral ventricles	At 6 y of age: unremarkable	At 8 months of age: hypoplastic corpus callosum, moderate dilatation of ventricles	At 13 y of age: unremarkable	N/A	N/A	Periventricular and subcortical white matter abnormalities, dilated ventricles	At 4 y of age: thin corpus callosum, delayed myelination	At 14 y of age: unremarkable	At 8 y of age: unremarkable	N/A
Neuromuscular												
Axial hypotonia	+	+	+	+	+	+	+	+	+	+	-	+
Gait disturbance (broad-based, ataxic, imbalanced)	+	+	+	N/A	+	N/A	-	N/A	-	N/A	+	-
Movement disorder	-	-	Choreoathetotic-like movements	Choreoathetotic/dystonic dyskinesia	-	Spastic/dyskinetic	-	-	-	-	-	-
Reflexes	Hyperreflexia	N/A	N/A	Hyperreflexia	Normal	Hyperreflexia	Normal	N/A	Hyperreflexia	N/A	Normal	N/A
Epilepsy												
Yes/No	+	-	+	-	+	+	+	+	+	+	-	(-) one event reported
Age of onset	5 y	7 y	N/A	-	13 y	5 y	8 y	9 m	3 y	9 y	N/A	9 m
Type / Frequency	Tonic-clonic	Lennox-Gastaut-like	N/A	-	Tonic-clonic	BMS-like, gaze deviation, cloni	Four events (not recorded)	Generalized	GTCs, starting spells, limb jerking, head drops - as many as 100 a day	Tonic	N/A	N/A
EEG patterns	ETPs: multifocal spike wave complexes (temporo-occipital) and generalized sharp wave complexes up to 4/sec	N/A	Unremarkable	Nonspecific global dysfunction, epileptiform paroxysms	Bilateral centrottemporal sharp waves and spikes	Series of sharp wave complexes (left frontal) 2-4 s, up to 40 s	Normal	Generalized spike wave complexes	Epileptic encephalopathy	N/A	Unremarkable	Unremarkable

Table 1. continued

Treatment	Family A	Family B	Family C	Family D	Family E	Family F	Family G	Family H	Family I	Family J	Family K	Family L
Levetiracetam, Clobazam	Lamotrigine, Topiramate, Valproic acid; VNS	N/A	Several AEDs, currently: lamotrigine 200/300; VNS	-	Levetiracetam	Levetiracetam, Lamotrigine, Valproate, Zonisamidi; VNS	Sodium valproate syrupe	Piracetam syrupe	Kepra, zonisamide, clobazepam, valproate	Sodium valproate syrup/ Divalproex sodium tablets	N/A	N/A
Pulmonary												
Respiratory distress	-	-	-	+	-	-	-	+	-	-	-	-
Interstitial lung disease/fibrosis	No clinical signs (no interstitial lung disease on chest radiography)	No clinical signs (no interstitial lung disease on chest radiography)	No clinical signs (no interstitial lung disease on chest radiography)	N/A (chest-radiograph during RSV-infection; no CT)	- (Normal CT chest, no interstitial lung disease on chest radiography)	No clinical signs (no interstitial lung disease on chest radiography)	No clinical signs	N/A	No clinical signs	No clinical signs (no interstitial lung disease on chest radiography)	No clinical signs	N/A
Gastrointestinal												
Malabsorption	-	-	(+) confirmed celiac disease	+	-	-	-	+	-	-	-	+
Diarrhea	-	-	(+)	-	-	-	-	+	-	-	-	-
Other findings												
Recurrent infections	-	-	-	+	-	-	-	+	-	-	-	-
Hepatomegaly	-	-	-	+	-	-	-	-	-	-	-	-
Visual (strabismus)	-	-	-	+	-	N/A	-	-	+	-	-	+
Anemia	(+) confirmed thalassaemia minor	-	-	+	-	-	-	+	-	+	-	-
Others (kidney, cardiac)	-	-	-	+	-	-	-	-	Unilateral renal reflux, congenital heart disease (VSD, ASD)	-	-	-

+ = present; (+) = mild; - = absent; N/A = not available, y = Year, m = Month, SD = Standard deviation.

Table 2. Frequency of main phenotypic findings in this study compared to previously published cases.

Phenotype	HPO	this cohort (n = 15)	literature (n = 13)	total (n = 28)
Growth parameters/development				
Short stature (+ growth retardation)	HP:0004322	7/15	2/6	9/21
Decreased body weight (+ poor weight gain)	HP:0004325	9/15	8/13	17/28
(borderline) microcephaly (< - 2 SD at last clinical examination)	HP:0040196	4/10	0/4	4/14
Neurological findings				
Global developmental delay, intellectual disability	HP:0001263, HP:0001249	15/15	13/13	28/28
Speech or motor regression	HP:0002376	6/10	1/5	7/15
Behavioural abnormalities (+ irritability)	HP:0000708	7/15	11/12	18/27
Brain abnormalities (dilated lateral ventricles, thin corpus callosum, brain atrophy)	HP:0012443	5/11	7/9	12/20
Gait disturbance (ataxic, unbalanced)	HP:0002066	5/9	3/5	8/14
Movement disorder (dystonia, spasticity)	HP:0001332	4/14	9/11	13/25
Axial hypotonia	HP:0008936	12/15	11/12	23/27
Seizures, EEG abnormalities	HP:0001250, HP:0002353	11/15	9/12	20/27
Pulmonary findings				
Respiratory distress in infancy	HP:0002098	2/15	9/13	11/28
Recurrent respiratory infections	HP:0002205	2/15	11/12	13/27
Interstitial changes on chest-CT	HP:0006530	0/1	7/9	7/10
Other symptoms				
Hepatomegaly	HP:0002240	1/15	4/12	5/27
Diarrhea	HP:0002014	2/15	8/11	10/26
Cardiovascular abnormality	HP:0001626	2/15	3/13	5/28
Ophthalmologic findings (strabismus)	HP:0000486	3/14	5/13	8/27
Hematological system (anemia)	HP:0001903	2/15	8/13	10/28
Angiomatosis-like cerebral lesions (post-mortem examination)	HP:0009145	0/0	3/3	3/3

individuals (ages five, six, eight and 19) had microcephaly (SD below -2). Short stature and decreased body weight were observed in seven and nine individuals, respectively, with five individuals having both. All 15 individuals showed global developmental delay and later intellectual disability (ID), which in most cases was classified as moderate or severe. Nine children were non-verbal at the last assessment, and five could speak only a few rudimentary words. In four cases, speech regression occurred after 1–3 years of age, and the siblings (individual 1 and 2) had motor regression starting from the age of six. Behavioral abnormalities (hyperactivity, impulsive, aggressive, anxious and autistic behavior) were reported in seven individuals. All 15 individuals had variable neuromuscular involvement: 12 had truncal hypotonia, five individuals were never able to walk and four developed hyperkinetic movement disorder, spasticity or hyperreflexia. Two depended on a wheelchair for long distances and five had an unsteady, wide gait. Seizures occurred in 11 individuals, with age of onset ranging from nine months to 13 years. In individual 5, epileptiform discharges were documented but no clinical seizure was observed. In six individuals, multiple antiepileptic drugs were tried due to intractable seizures and two children were fitted with a vagus nerve stimulation (VNS) device. Brain abnormalities (dilated ventricles, corpus callosum hypoplasia, mild cortical atrophy and delayed myelination) were diagnosed in five individuals, while six had unremarkable brain MRI scans. Other less common findings included strabismus ($n = 3$), diarrhea and/or malabsorption ($n = 3$), recurrent infections

($n = 2$), anemia ($n = 2$), congenital heart defect ($n = 2$) and unilateral renal reflux ($n = 1$).

Molecular findings

In addition to the recurrent missense variant p.(Asp148Tyr), we identified nine novel variants, including one start-loss variant, three missense variants, two single amino acid in-frame deletions, two nonsense and one C-terminal frameshift variant. The localization of the variants, their level of conservation and the pathogenicity prediction using different in silico tools are summarized in Fig. 1b–d and Supplementary Table 2. The results of the segregation analysis are shown in Supplementary Fig. 2. While RT-qPCR showed no clear difference in *NHLRC2* expression levels between patient and control LCLs (Fig. 2a), Western blot showed a clear reduction in *NHLRC2* protein levels in all patient samples tested compared to control samples (Fig. 2c, d). Consistent with the RT-qPCR results, Sanger sequencing of cDNA from patients' LCLs confirmed all variants at the mRNA level (Fig. 2b and Supplementary Fig. 3).

In one individual with early pulmonary distress and severe multisystem involvement (individual 5), the recurrent missense variant p.(Asp148Tyr) was detected in trans with an N-terminal nonsense variant p.(Gln50*). In seven individuals with overall less severe neurological manifestations and without pulmonary symptoms, ES detected the known pathogenic variant p.(Asp148Tyr) in homozygous state. The homozygous *NHLRC2* start-loss variant c.1A>G was detected in four individuals from two




Fig. 1 Pedigrees and identified NHLRC2 variants in 15 novel individuals. **a** Family pedigrees. Affected individuals are depicted in black and numbered. Healthy carriers are marked by ● and/or x. Same symbols represent parents that are carriers of the same variant whereas different symbols state parents are carriers of different variants. **b** NHLRC2 protein and variants identified in this (above) or previous (below) studies. Novel variants are shown in red, previously reported variants in black. Variants detected in homozygous state are underlined and variants detected in compound heterozygous state are linked by a dotted line. **c** Conservation of amino acid positions affected by identified missense variants (according to MutationTaster2021 [21]) and **d** Position within the 3D structure of NHLRC2 affected by the missense variants according to AlphaFold [15, 22] model of NHLRC2 (Uniprot: Q8NBF2).




Fig. 2 Expression of *NHLRC2* variants in patients' cell lines. **a** RT-qPCR of LCLs of individuals 1-5 in comparison to controls: expression of *NHLRC2* relative to GAPDH. **b** Sanger sequencing of cDNA from the same LCL samples. Shown are the respective variant positions as identified on genomic DNA level. Wildtype nucleotides are shown in black, variants in red. (extended sequencing data can be found in Supplementary Fig. 3) **c** Western Blot of *NHLRC2* in whole cell lysates from patients' or healthy control lymphoblastoid cell lines. β -Actin is shown as loading control. **d** Quantification of *NHLRC2* intensity relative to β -Actin with Image J.

unrelated families (A and F) in association with a severe and progressive neurological phenotype without pulmonary disease. The variant is absent in controls according to the gnomAD database and the closest in-frame alternative translation start codon is located at c.433, p.145. By analyzing the individual vcf files we confirmed that they share the same disease haplotype (Supplementary Fig. 4). *NHLRC2* protein levels, extracted from LCL-derived cells of individuals 1 and 2, were strongly reduced compared to control samples (Fig. 2c, d).

In individual 4, presenting with neuroregression and epileptic encephalopathy, a nonsense variant p.(Leu584*) was detected in combination with a rare missense variant p.(Asp692Tyr) affecting a moderately conserved residue located in the β -strand domain. The nonsense variant is predicted to undergo nonsense-mediated decay (NMD) and Western blotting showed a strong reduction in *NHLRC2* protein levels compared to control samples (Fig. 2c, d).

Two missense variants p.(Gln365Pro) and p.(Phe462Ser), affecting highly conserved residues within the β -propeller domain, were detected in compound heterozygous state in individual 6, in association with speech regression, mild gait disturbance and medication-responsive epilepsy. While the former variant is listed once in heterozygosity in gnomAD, the latter has an allele frequency of 0.1% in the non-Finnish European population.

In individual 10, presenting with a severe disease including respiratory distress, malabsorption, anemia and recurrent infections, ES detected a single amino acid in-frame deletion affecting the highly conserved residue p.Glu33. Individual 11 was compound-heterozygous for an in-frame deletion p.(Gln333del) and a C-terminal frameshift variant that is unlikely to undergo NMD. She had severe neurological manifestations including epileptic encephalopathy and was previously reported with *USP19* as a candidate gene [19].

In vitro studies of missense and in-frame deletion variants

Firstly, to test the impact of the non-truncating variants identified in patients from our study ($n = 5$), secondly to compare them with previously reported missense variants associated with pulmonary symptoms ($n = 4$) and thirdly to critically review the strongly reduced *NHLRC2* protein levels observed in LCLs, we cloned all nine non-truncating *NHLRC2* variants together with a wildtype control into pcDNA3. For reliable detection, we added a C-terminal Flag-tag (Fig. 3a, b, Supplementary Table 1).

Western blot of HEK293 cells transfected with these different *NHLRC2* constructs (Fig. 3c, d) showed a reproducible reduction in *NHLRC2* protein levels for the recurrent p.(Asp148Tyr) variant. It also showed a strong reduction in mutant *NHLRC2* protein levels for the p.(Glu33del) variant identified in the severely affected individual 10 and for the p.(Asp75Val), p.(His143Pro), p.(Pro338Leu) and p.(Glu365Pro) missense variants. The first three missense variants were all identified in trans with the recurrent p.(Asp148Tyr) variant in individuals with a severe multisystem phenotype including respiratory symptoms (Fig. 3e) [6, 7]. The p.(Glu365Pro) variant was detected in trans with the p.(Phe462Ser) variant in individual 6 without pulmonary involvement. It is noteworthy that the p.(Phe462Ser) variant as well as the p.(Gln333del) variant identified in individual 11 in trans with p.(Gln705Leufs*4) and the missense variant p.(Asp692Tyr) detected in trans with p.(Leu584*) in individual 4 showed only slightly reduced protein levels.

To investigate for a possible genotype-phenotype correlation, we compared these findings to variants and their combinations identified in individuals with and without pulmonary disease (Fig. 3e). We observed a correlation of remaining *NHLRC2* protein levels with phenotype severity: higher reduction in total *NHLRC2* protein level correlated with more severe phenotypes, ranging from milder over more severe neurological symptoms to additional lung disease (Fig. 3f).




Fig. 3 **In vitro studies of missense and in-frame deletion variants.** **a** Schematic map of NHLRC2-Flag expression constructs in pcDNA.3 **b** Workflow of transfection of HEK293 cells with NHLRC2-Flag expression constructs along with GFP control plasmid. **c** Western Blot of HEK293 cells transfected with NHLRC2 expression constructs: anti-Flag as well as anti-NHLRC2 and anti-GFP for loading control. **d** Quantification of NHLRC2 intensity relative to β -Actin with Image J. **e** Comparison of genotypes associated with pulmonary involvement and those without. Respective number of individuals carrying the depicted combination of variants is shown in the gray bars to the left or right, respectively. Variant combinations seen in individuals in this cohort are highlighted in red, variant combinations reported in the literature are shown in black. **f** Theoretical calculated sum of the protein levels of both NHLRC2 alleles for the variant combinations shown in Fig. 3e (intensities are taken from quantification shown in Fig. 3d; frameshift and nonsense variants are counted as (0) and correlation of calculated total protein level to phenotype severity).

In silico modeling of non-truncating variants

To further investigate how the *NHLRC2* variants that still result in stable NHLRC2 protein, as deduced from the in vitro overexpression assays, affect the folding of the protein, we modeled the missense variants p.(Asp148Tyr), p.(Asp692Tyr) and p.(Phe462Ser) and the

p.(Gln333del) variant with the AlphaFold tool (Fig. 4). In the recurrent missense variant p.(Asp148Tyr), the replacement of the negatively charged amino acid aspartate by the polar, uncharged tyrosine is predicted to result in the loss of several hydrogen bonds (Fig. 4a, b). Analysis of the internal model accuracy estimates as




Fig. 4 **In silico modeling of non-truncating variants.** **a** AlphaFold model of the wildtype NHLRC2 protein (Uniprot: Q8NBF2) and location of p.Asp148 within. Zoom-in: Hydrogen bonds formed between Asp148 and other amino acids. **b** AlphaFold model of the p.(Asp148Tyr) mutant NHLRC2 protein and zoom-in on the altered and lost hydrogen bonds. **c** pLDDT Scores from the AlphaFold models for each amino acid position for both the wildtype model and the p.Asp148Tyr variant. **d** pLDDT score in each amino acid position for the p.Asp148Tyr variant subtracted by the respective value in the wildtype model. **e** Schematic of hydrogen bonds between the wildtype and mutant amino acid position according to AlphaFold predictions of the other three variants with relevant remaining stable protein levels according to western blots (Fig. 3e). **f–h** MaSIF prediction of a potential binding site on AlphaFold models for (f) the p.(Gln333del), (g) the p.(Phe462Ser) as well as (h) the p.(Asp692Tyr) variant and position. Respective amino acid positions within the model are marked by pink dots and pointed at by the pink arrows.

measured by the pLDDT score at the p.148 position in the wildtype vs. the mutant model revealed a prediction accuracy reduction at the position of the exchange. Notably, this position has previously been predicted with high certainty in the wildtype (Fig. 4c, d) and is also predicted with certainty in other models not affecting the same amino acid position (Supplementary Fig. 5). All four other variants analyzed also lead to the loss of at least one hydrogen bond formed at the wildtype position of the respective variant (Fig. 4e).

Further analysis of the amino acid positions affected by the missense variants with the MaSIFtool suggested possible protein binding sites in the vicinity to amino acids Gln333, Phe462 and Asp692. We therefore modeled the respective variants and their potential effect on these binding sites. While we observed a decrease in the probability of protein-protein interaction at Gln333 and Phe462 for the p.(Gln333del) and p.(Phe462Ser) variants, respectively, we could not detect such an effect for the p.(Asp692Tyr) variant (Fig. 4e–h, Supplementary Figure 5).

DISCUSSION

Only 13 individuals from eight unrelated families of different geographical origin with biallelic pathogenic *NHLRC2* variants have been published. Therefore, *NHLRC2* has only a limited evidence class assignment in the curation database GenCC. In all previously published cases, the recurrent missense variant p.(Asp148Tyr) was detected. When FINCA syndrome was first characterized, this missense variant was reported in three individuals in trans with the truncating variant p.(Arg201Glyfs*6) [5]. All of these first patients presented with a severe multisystem phenotype including progressive respiratory disease. In total, 11 out of 13 individuals with *NHLRC2*-related disease showed respiratory symptoms and six died of respiratory failure before the age of three years. In contrast, only one child from our cohort (individual 5) had an early fatal course with pulmonary involvement. Notably, the combination of the recurrent missense variant p.(Asp148Tyr) and a truncating variant p.(Gln50*) was also detected here. In three previously published families, the recurrent missense variant occurred in combination with a second missense variant p.(Asp75Val), p.(His143Arg) or p.(Pro338Leu) in a total of five individuals with pulmonary disease [6, 7].

Only a few children without progressive pulmonary symptoms have been reported so far. In four of them, the recurrent variant was present in the homozygous state and once it was detected in trans with the missense variant p.(Gly326Val) [7, 8]. In our cohort, homozygosity for the recurrent variant p.(Asp148Tyr) was found in six children from five unrelated families. In agreement with the cases mentioned above, these individuals did not have respiratory symptoms and were overall less severely affected.

In addition, we describe the first eight individuals with an *NHLRC2*-associated disease, in whom the recurrent variant p.(Asp148Tyr) was not detected. All of those presented with a variable progressive clinical course, comprising global developmental delay, and various neuromuscular symptoms. Only one child had a more pronounced multisystem phenotype including respiratory distress, recurrent infections, malabsorption and anemia (individual 10, p.(Glu333del)). In two individuals with severe neurological manifestation including epileptic encephalopathy, the combination of a nonsense/frameshift variant and a non-truncating variant was detected (individual 4: p.[Leu584*];[Asp692-Tyr], individual 11: p.[Gln333del];[Gln705Leufs*4]). In contrast, individual 6, carrying the two missense variants p.[Gln365Pro];[-Phe462Ser], tended to have a milder clinical course. In four individuals from two unrelated families with progressive neurological manifestations and intractable seizures, the same homozygous disease haplotype containing a start-loss variant was detected (Supplementary Fig. 4). It is currently unclear whether a rescue mechanism is involved, or whether a significantly truncated protein is formed that cannot be detected with the antibody used

here. To our knowledge, no individuals with biallelic complete LoF variants have been described. Notably, a complete knockout also results in embryonic lethality in mice [20].

Overall, there appears to be variability in the time course and severity of clinical manifestations in individuals with biallelic *NHLRC2* variants. Studying different non-truncating variants and linking their effects on *NHLRC2* protein levels revealed a putative genotype-phenotype correlation: variants leading to severely reduced protein levels (either in homozygous or in compound-heterozygous state with another severe missense or frameshift/nonsense variant) were associated with an early onset multisystem phenotype including pulmonary disease. When the sum of *NHLRC2* protein levels from both alleles appears to exceed a certain critical level, a phenotype without progressive respiratory symptoms was observed (Fig. 3e, f). This may explain why the recurrent p.(Asp148Tyr) variant, resulting in reduced but still detectable remaining protein levels, is associated with a more severe phenotype with pulmonary involvement when in trans with a LoF variant (e.g. nonsense, frameshift or one of the severe missense variants p.(Asp75Val), p.(Pro338Leu), p.(His143Pro)), whereas homozygosity for this variant results in a milder phenotype without pulmonary disease. Interestingly, we also observed a tendency in the group without reported lung involvement. The lower the total protein level, the earlier and more pronounced the neurological manifestations occurred (e.g., intractable seizures and epileptic encephalopathy seen in individuals 4 and 11). Notably, in silico modeling of variants predicted to result in stable *NHLRC2* protein levels revealed possible effects on proper *NHLRC2* function via alteration of protein binding sites (Fig. 4). Since we had only cloned the previously published missense variants, which were associated with pulmonary involvement, it would be interesting to know whether overexpression of the p.(Gly326Val) variant (detected in trans with the recurrent missense variant in a patient without pulmonary disease) [8] also results in a stable but presumably reduced product. Under this assumption, in silico models of the p.(Gly326Val) variant showed a reduction in prediction accuracy at the affected amino acid position (Supplementary Fig. 5), potentially implying interference of the variant with the local structural context.

Currently, it is difficult to classify non-truncating variants as (likely) pathogenic according to the ACMG scoring framework, especially in autosomal recessive disorders when the second variant is not known to be pathogenic. In this situation, the criteria PM2 and PP3 are likely to be assigned to most *NHLRC2* missense variants and subsequently classified as a variant of uncertain significance (VUS). The small number of pathogenic *NHLRC2* variants described so far and the lack of knowledge about the function of *NHLRC2* are likely to hinder a molecular diagnosis in unsolved cases. In this regard, we consider it useful to apply the protein modeling approach presented here and to perform a comprehensive clinical characterization of the affected individual. We recommend that AlphaFold mutant protein modeling and MaSIF prediction be calculated to check whether the variant is localized to a potentially functionally relevant region or substantially alters the tertiary structure of the protein. The criterion PM1 could then be applied at the level of supporting evidence (PM1_sup). However, we urgently need basic knowledge of the physiological function and interaction partners or substrates of *NHLRC2* to validate the predicted effects and to establish a possible functional readout.

In addition, the specificity of the phenotype criterion (PP4) could be upgraded to moderate level of evidence, if additional symptoms besides NDD/ID are present and comprehensive genetic testing has been performed. In our opinion, this should include symptoms from different systems, such as neurological, pulmonary, gastrointestinal or hematological.

Taken together, our data broaden the hitherto known phenotypic spectrum, extend the allelic series and emphasize that rare biallelic

NHLRC2 variants should be considered relevant in patients with NDD/ID, movement disorders, neuroregression and epilepsy even in the absence of pulmonary findings. To explain this variable phenotypic spectrum, we propose a genotype-phenotype correlation of residual *NHLRC2* protein level and function with phenotype severity. Follow-up studies reporting the clinical course of affected individuals would be important to understand whether all affected individuals have a progressive multi-organ disease with variability in age of onset and severity of clinical manifestations, or whether there is indeed a distinct genotype-phenotype correlation. In this respect, our proposed model is limited and needs to be critically evaluated in further publications.

DATA AVAILABILITY

Pathogenic variants were submitted to the ClinVar database Accession [ID: VCV001727064.1 VCV001727063.1 VCV001727062.1 VCV001727061.1 VCV001727060.1]. Further original sequencing and experimental data are available upon reasonable request.

CODE AVAILABILITY

The source code for AlphaFold is publicly available at <https://github.com/deepmind/alphafold>. The source code for MaSIF is publicly available at <https://github.com/LPDI-EPFL/masif>. All analysis scripts for processing AlphaFold models and MaSIF predictions are available on request.

REFERENCES

- Biterova E, Ignatyev A, Uusimaa J, Hinttala R, Ruddock LW. Structural analysis of human *NHLRC2*, mutations of which are associated with FINCA disease. *PLoS One*. 2018;13:e0202391.
- Nishi K, Iwaihara Y, Tsunoda T, Doi K, Sakata T, Shirasawa S, et al. ROS-induced cleavage of *NHLRC2* by caspase-8 leads to apoptotic cell death in the HCT116 human colon cancer cell line. *Cell Death Dis*. 2017;8:3218.
- Haney MS, Bohlen CJ, Morgens DW, Ousey JA, Barkal AA, Tsui CK, et al. Identification of phagocytosis regulators using magnetic genome-wide CRISPR screens. *Nat Genet*. 2018;50:1716–27.
- Hiltunen AE, Vuolteenaho R, Ronkainen VP, Miinalainen I, Uusimaa J, Lehtonen S, et al. *Nhlrc2* is crucial during mouse gastrulation. *Genesis* 2022;60:e23470.
- Uusimaa J, Kaarteenoaho R, Paakkola T, Tuominen H, Karjalainen MK, Nadaf J, et al. *NHLRC2* variants identified in patients with fibrosis, neurodegeneration, and cerebral angiomas (FINCA): characterisation of a novel cerebropulmonary disease. *Acta Neuropathol*. 2018;135:727–42.
- Brodsky NN, Boyarchuk O, Kovalchuk T, Hariyan T, Rice A, Ji W, et al. Novel compound heterozygous variants in *NHLRC2* in a patient with FINCA syndrome. *J Hum Genet*. 2020;65:911–5.
- Rapp CK, Van Dijk I, Laugwitz L, Boon M, Briassoulis G, Ilia S, et al. Expanding the phenotypic spectrum of FINCA (fibrosis, neurodegeneration, and cerebral angiomas) syndrome beyond infancy. *Clin Genet*. 2021;100:453–61.
- Badura-Stronka M, Śmigiel R, Rutkowska K, Szymańska K, Hirschfeld AS, Monkiewicz M, et al. FINCA syndrome-Defining neurobehavioral phenotype in survivors into late childhood. *Mol Genet Genom Med*. 2022;10:e1899.
- Rillig F, Grüters A, Bäumer T, Hoffmann GF, Choukair D, Berner R, et al. The Interdisciplinary diagnosis of rare diseases-results of the translate-NAMSE Project. *Dtsch Arztebl Int* [Internet]. 2022 Jul;(Forthcoming). Available from: <https://doi.org/10.3238/arztebl.m2022.0219>
- Sobreira N, Schiettecatte F, Valle D, Hamosh A. GeneMatcher: a matching tool for connecting investigators with an interest in the same gene. *Hum Mutat*. 2015;36:928–30.
- Landrum MJ, Lee JM, Riley GR, Jang W, Rubinstein WS, Church DM, et al. ClinVar: public archive of relationships among sequence variation and human phenotype. *Nucleic Acids Res* 2014;42:D980–5.
- Philippakis AA, Azzariti DR, Beltran S, Brookes AJ, Brownstein CA, Brudno M, et al. The Matchmaker Exchange: a platform for rare disease gene discovery. *Hum Mutat*. 2015;36:915–21.
- Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med*. 2015;17:405–24.
- Neitzel H A. routine method for the establishment of permanent growing lymphoblastoid cell lines [Internet]. Vol. 73, Human Genetics. 1986. p. 320–6. Available from: <https://doi.org/10.1007/bf00279094>

- Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly accurate protein structure prediction with AlphaFold. *Nature* 2021;596:583–9.
- Gainza P, Sverrisson F, Monti F, Rodolà E, Boscaini D, Bronstein MM, et al. Deciphering interaction fingerprints from protein molecular surfaces using geometric deep learning. *Nat Methods*. 2020;17:184–92.
- Steinhaus R, Boschann F, Vogel M, Fischer-Zirnsak B, Seelow D. AutozygosityMapper: Identification of disease-mutations in consanguineous families. *Nucleic Acids Res* [Internet]. 2022 Apr; Available from: <https://doi.org/10.1093/nar/gkac280>
- Vogt G, Verheyen S, Schwartzmann S, Ehmke N, Potratz C, Schwerin-Nagel A, et al. Biallelic truncating variants in *ATP9A* cause a novel neurodevelopmental disorder involving postnatal microcephaly and failure to thrive. *J Med Genet* [Internet]. 2021 Jun; Available from: <https://doi.org/10.1136/jmedgenet-2021-107843>
- Eldomery MK, Coban-Akdemir Z, Harel T, Rosenfeld JA, Gambin T, Stray-Pedersen A, et al. Lessons learned from additional research analyses of unsolved clinical exome cases. *Genome Med*. 2017;9:26.
- Perez-Garcia V, Fineberg E, Wilson R, Murray A, Mazzeo CI, Tudor C, et al. Placentation defects are highly prevalent in embryonic lethal mouse mutants. *Nature* 2018;555:463–8.
- Steinhaus R, Proft S, Schuelke M, Cooper DN, Schwarz JM, Seelow D. MutationTaster2021. *Nucleic Acids Res*. 2021;49:W446–51.
- Varadi M, Anyango S, Deshpande M, Nair S, Natassia C, Yordanova G, et al. AlphaFold Protein Structure Database: Massively expanding the structural coverage of protein-sequence space with high-accuracy models [Internet]. Vol. 50, *Nucleic Acids Research*. 2022. p. D439–44. Available from: <https://doi.org/10.1093/nar/gkab1061>

ACKNOWLEDGEMENTS

We are grateful to the families who contributed to this study. We thank Gabriele Hildebrand and Steve Viergutz for great technical assistance and Kalene van Engelen for help with data gathering for individual 4. Figure 1b, 3a, b, e, f, were in part created with BioRender.com.

AUTHOR CONTRIBUTIONS

FB, HLS and MZ wrote the manuscript. DH, RM, NE, MJ, JRL, and TBB critically reviewed the manuscript. FB, MD, CS, NE, ND, TBB, MO, AA, JS, JP, KMD, ND, MM, AE, BB, DGC, ZF, SMS, SAM, NA, FR, and DH saw and evaluated the patients. FB, HLS, NE, DH, MA, TBB, MO, JP, HO, KP, DGC and RM analyzed their sequencing data. HLS, FB, and MJ designed and analyzed experiments. HLS, FB and BW performed experiments. MZ, HLS, and DS performed bioinformatic analyses.

FUNDING

Dr. Sczakiel and Dr. Danyel are participants in the (Junior) BIH Charité Clinician Scientist Program funded by the Charité – Universitätsmedizin Berlin, and the Berlin Institute of Health at Charité (BIH). Dr. Boschann is a participant in the Clinician Scientist Program (CS4RARE) funded by the Alliance4Rare and associated with the above-mentioned BIH Charité Clinician Scientist Program. The sequencing for individual 4 was performed under the Care4Rare Canada Consortium funded by Genome Canada and the Ontario Genomics Institute (OGI-147), the Canadian Institutes of Health Research, Ontario Research Fund, Genome Alberta, Genome British Columbia, Genome Quebec, and Children’s Hospital of Eastern Ontario Foundation. Dr. Calame was supported by the U.S. National Institutes of Health (NIH) National Institute of General Medical Sciences (NIGMS) Medical Genetics Research Fellowship Program (T32 GM007526), Muscular Dystrophy Association Development Grant (873841, <https://doi.org/10.55762/pc.gr.147552>), and the Chao Physician Scientist Award. Dr. Lupski was supported by a U.S. National Human Genome Research Institute (NHGRI) and National Heart Lung and Blood Institute (NHBLI) grant to the Baylor-Hopkins Center for Mendelian Genomics (BHCMG, UM1 HG006542); NHGRI grant as part of the GREGoR Consortium (U01 HG011758); U.S. National Institute of Neurological Disorders and Stroke (NINDS) (R35NS105078), Muscular Dystrophy Association (MDA) (512848), and Spastic Paraplegia Foundation Research Grant. Open Access funding enabled and organized by Projekt DEAL.

ETHICAL APPROVAL

This study adheres to the principles set out in the Declaration of Helsinki and was approved by institutional Ethics Committees of Charité –Universitätsmedizin (EA2/177/18).

COMPETING INTERESTS

J.R.L. has stock ownership in 23andMe, is a paid Consultant for Genome International, and is a co-inventor on multiple U.S. and European patents related to molecular diagnostics for inherited neuropathies, genomic disorders, eye diseases, and bacterial genomic fingerprinting. All other authors declare no competing commercial interest. ML is an employee of GeneDx, LLC.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41431-023-01382-0>.

Correspondence and requests for materials should be addressed to Felix Boschann.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023